Ambea AB (AMBEA) Fair Value & Analysis
Healthcare · SE · Market cap 11.6B SEK
Fair value as of: Jul 19, 2026
From 24 valuation models · updated 21 days ago
Share price −1.0% over the past month.
A solid business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- A fairly wide model range (kr 105.48 to kr 194.84) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 19, 2026.
How to read this chart
60‑month range kr 29.68 – kr 159.00 · fair‑value band kr 105.48 – kr 194.84 · the kr 143.00 price screens above the kr 140.64 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 19, 2026.
Analysis
Ambea AB (AMBEA) currently trades at kr 143.00, while our model-based Fair Value estimate is kr 140.64, implying the stock looks roughly 1.7% fairly valued today. The Quality Score stands at 61/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Ambea AB generated revenue of 16.7B SEK at a net margin of 4.3%. Revenue grew 15.5% year over year. It earns a return on equity of 14.2%. Net debt stands at 12.5B SEK. Fundamentals as of Jul 19, 2026
Our scenario range runs from kr 105.48 (bear case) to kr 194.84 (bull case); at kr 143.00, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 7% below its 52-week high and 34% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at -2%, AMBEA screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (kr 317.14) versus Asset-Based (kr 43.34). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 59 · Market factors (momentum, volatility) 63
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Ambea AB (publ) provides elderly care, disability care, and psychosocial support for the elderly and people with disabilities in Sweden, Norway, and Denmark. It operates through Nytida, Vardaga, Stendi, Altiden, and Klara segments.
Full company description
Ambea AB (publ) provides elderly care, disability care, and psychosocial support for the elderly and people with disabilities in Sweden, Norway, and Denmark. It operates through Nytida, Vardaga, Stendi, Altiden, and Klara segments. The company offers social care services; schools for children and youth with neuropsychiatric disorders under the Nytida brand; nursing homes and home care services for elderly people under the Vardaga brand; and social care for adults, children, and youth, as well as personal assistance under the Stendi brand. It also offers disability care, nursing home, home care, and rehabilitation services under the Altiden brand. In addition, the company offers staff solutions for social welfare services, including ambulatory care teams and student health service staffing under the Klara brand. Further, it develops and offers skills development training and coaching services in disability care, social services field, aged care, and schools under the Lära brand; and care youth and families as well as residential facilities personal assistance, daily activity units and rehabilitation for people with physical and intellectual disabilities, and psychosocial problems under the Validia brand. Ambea AB (publ) was incorporated in 1993 and is headquartered in Solna, Sweden.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Ambea AB reported revenue of kr 16.0B in FY2025 versus kr 11.5B in FY2021, a compound +8.7%/yr. Reported net income was kr 665M in FY2025, compounding +29.4%/yr from FY2021.
Watch AMBEA: get an alert when its fair value changes →
Peer Group
Medical Care Facilities · 262 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.58 SGD | 1.44 SGD | -44% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare Ambea AB with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Ambea AB (AMBEA) overvalued or undervalued?
What is the fair value of AMBEA?
What is the quality score of AMBEA?
What is the revenue of Ambea AB (AMBEA)?
What is the net profit margin of AMBEA?
Does Ambea AB pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Ambea AB and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.